Press Releases

Results Found (130)
July 27, 2015
Yissum Introduces a Novel Technology for Drug Screening and Testing of...

The novel technology by Prof. Nissim Benvenisty utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs

July 2, 2015
Merck KGaA acquires Qlight Nanotech

Qlight Nanotech’s staff will remain at the Company’s site at the Hebrew University of Jerusalem, and will function as the research base for Merck for quantum-materials for the display and lighting industry

June 18, 2015
Yissum and ICL Expand Research Collaboration in the Area of Advanced Materials

Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of advanced materials with ICL (NYSE and...

May 25, 2015
A New Drug on Market! Santen announces Approval of Ikervis for EU Marketing...

Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission. Ikervis is approved for treatment of severe keratitis in adult patients with dry eye...

April 28, 2015
Yissum Introduces Novel Method for Increasing Shelf Life of Leafy Greens

The invention to be presented at Agritech Israel 2015

March 23, 2015
ISA Scientific, Yissum, Hadasit and the Kennedy Trust for Rheumatology...

The licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists, Raphael Mechoulam, Professor of medicinal chemistry, and Ruth Gallily, Professor of immunology, both from the...

January 26, 2015
Yissum and Phytotech Medical to Collaborate on Novel Delivery System for...

Phytotech Medical went public on the Australian Securities Exchange raising AUS$5.9 million dollars 

January 25, 2015
Yissum Start Up Melodea’s Chairman of the Board, Mr. Tord Gustafsson, ...

Prize awarded for contribution to collaboration between Melodea and Holmen

December 8, 2014
Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou...

Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, announced today that it has received US $3 million investment from Guangxi Wuzhou Pharmaceutical Group Co.,...

October 6, 2014
Lockheed Martin and Yissum Sign Long Term Research Collaboration Agreement

Yaacov Michlin, CEO of Yissum, said at the signing ceremony: “The framework agreement we signed today sets the ground for a wide range of potential areas of research collaboration between the two parties”. 

September 17, 2014
Avraham Pharmaceuticals Raises $4.5 Million in Additional Investment Led by...

The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016 

July 24, 2014
Atox Bio Closes $23 Million Investment

Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections